Home » Neurogenetics Announces Name Change to TorreyPines Therapeutics
Neurogenetics Announces Name Change to TorreyPines Therapeutics
March 17, 2005
Neurogenetics, a clinical-stage biopharmaceutical company focused on discovering and developing breakthrough small molecule drugs to treat diseases and disorders of the central nervous system, has changed its name to TorreyPines Therapeutics. The company also reported it has completed a $34.8 million Series C financing to advance its product development programs in migraine and Alzheimer's disease.
BioSpace (http://www.biospace.com/news_story.cfm?StoryID=19402020&full=1)
KEYWORDS FDAnews Drug Daily Bulletin
Upcoming Events
-
21Oct